Merck & Company Inc. (new) ($MRK) Stock Forecast: Up 2.0% Today

What is Merck & Company Inc. (new)?

Merck & Co. is a pharmaceutical company with a reputation for innovation and strong financial performance. The stock showed a positive trend today, reflecting favorable market sentiment.

Why is Merck & Company Inc. (new) going up?

MRK stock is up 2.0% on Feb 3, 2026 16:11

• Merck & Co. (MRK) stock saw an uptick following the release of robust Q4 2025 financial results and positive FY 2026 earnings outlook.
• Optimism surrounds Merck's acquisitions and broad pipeline diversification, especially looking beyond the exclusivity of Keytruda, driving the positive market sentiment.
• An educational campaign by Bristol Myers Squibb and Johnson & Johnson about the factor XIa pathway may be influencing the upward movement, shining a light on the potential of novel anticoagulants for cardiovascular and thromboembolic conditions.
• Positive remarks by Jim Cramer regarding Merck's future prospects and its expansion beyond Keytruda are likely bolstering investor confidence in the company's growth trajectory.

MRK Price Chart

MRK Technical Analysis

MRK News

BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop

Bristol Myers Squibb (BMS) and Johnson & Johnson (J&J) have launched an educational campaign for healthcare professionals about the factor XIa pathway, ahead of upcoming Phase 3 data for their investigational anticoagulant, milvexian. This initiative aims to inform clinicians about unmet needs in cardiovascular and thromboembolic conditions and how factor XIa inhibitors could address them, particularly concerning the mechanism's potential to prevent dangerous clots without increasing bleeding risk. The campaign sets the stage for a potential launch, despite a prior setback with one Phase 3 trial and competition from existing and emerging anticoagulants.

https://www.fiercepharma.com/marketing/bms-jj-factor-physician-education-clot-busting-mechanism-x-factor-readouts

Jim Cramer on Merck & Co.: “I Think It Can Spread Out the Wealth”

Jim Cramer highlighted Merck & Co. (MRK) as a favorable stock, noting its strategic acquisitions to diversify beyond Keytruda. He praised the company's foresight in preparing for Keytruda's patent expiration by building a strong pipeline, including a potential blockbuster drug for chronic obstructive pulmonary disease. Analysts are also recognizing Merck's future potential beyond Keytruda exclusivity.

https://uk.finance.yahoo.com/news/jim-cramer-merck-co-think-122400720.html

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Merck & Co. announced strong financial results for the fourth quarter and full year 2025, driven by oncology and animal health, and increasing contributions from new products like WINREVAIR and CAPVAXIVE. The company reported fourth-quarter worldwide sales of $16.4 billion and full-year sales of $65.0 billion, demonstrating progress in its diverse pipeline and strategic acquisitions. Merck also provided a full-year 2026 financial outlook, anticipating worldwide sales between $65.5 billion and $67.0 billion.

https://www.pharmiweb.com/press-release/2026-02-03/merck-co-inc-rahway-nj-usa-announces-fourth-quarter-and-full-year-2025-financial-results

Merck & Co., Inc. (NYSE:MRK) Issues FY 2026 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) has released its FY 2026 earnings guidance, projecting EPS between $5.00 and $5.15 and revenue between $65.5 billion and $67.0 billion, falling short of analyst consensus. This lower outlook is attributed to anticipated patent expirations, notably Januvia, and increased acquisition spending. Despite missing Q4 EPS targets, the company saw strong revenue and continued demand for Keytruda, and announced a quarterly dividend of $0.85 per share.

https://www.marketbeat.com/instant-alerts/merck-co-inc-nysemrk-issues-fy-2026-earnings-guidance-2026-02-03/

MRK Earnings: Merck Q4 2025 sales and profit beat estimates

Merck & Co., Inc. reported a strong fourth quarter for fiscal 2025, with both sales and adjusted earnings surpassing analyst estimates. The company saw a 5% increase in total sales to $16.4 billion and a 19% jump in adjusted earnings per share to $2.04. Merck's CEO highlighted demand for key products like KEYTRUDA and benefits from recent acquisitions, while providing optimistic sales guidance for fiscal 2026.

https://news.alphastreet.com/mrk-earnings-merck-q4-2025-sales-and-profit-beat-estimates/

Trending Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.6% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 5.8% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 6.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 7.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 6.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.9% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 5.4% Today

Wingstop Inc. ($WING) Stock Forecast: Down 6.8% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 5.1% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 5.3% Today

Merck & Company Inc. (new) Price History

25.03.2024 - MRK Stock was up 5.2%

• Merck (MRK) showed a significant upward trend in trading.
• In Q1, the company exceeded expectations with its adjusted earnings.
• The strong sales of Keytruda and vaccines contributed to the positive earnings, prompting an improved company outlook.
• Investor confidence and optimism in Merck's growth and product range were evident in the market's positive response.

30.04.2024 - MRK Stock was down 0.6%

• Merck's agreement to acquire EyeBio for up to $3 billion may have raised concerns among investors about the company's financial health and the potential dilution of shareholder value.
• The market may have reacted negatively to the news of Merck's scientific collaboration deal with Korea's KAIST, as investors might be uncertain about the immediate benefits and long-term implications of this partnership.
• The Chronic Kidney Disease market forecast and the list of companies involved in this sector may have signaled increased competition for Merck, leading to a bearish sentiment among investors.
• Overall, the combination of these developments could have contributed to the bearish movement in Merck's stock today, as investors reevaluated the company's strategic decisions and competitive positioning in the market.

27.02.2024 - MRK Stock was up 5.2%

• Merck's stock experienced a strong bullish trend following the FDA approval of their new treatment for a deadly lung condition, Winrevair, which holds promising market potential.
• The positive outlook towards Merck was also supported by the FDA approval for their drug targeting pulmonary arterial hypertension in adults, demonstrating the company's dedication to creating impactful healthcare solutions.
• The general market recovery and the upsurge in S&P 500 index also played a role in the bullish movement of Merck's stock, reflecting a broader optimism among investors towards the pharmaceutical industry.
• With these recent milestones and endorsements, Merck's innovative approach to healthcare solutions is expected to fuel further growth and investor confidence in the company's future prospects.

06.08.2023 - MRK Stock was down 3.8%

• The bearish movement in MRK's stock could be attributed to the following factors:
• 1. Market sentiment: The overall bearish sentiment in the Asian markets, as mentioned in an article from WNYT, may have influenced the decline in MRK's stock price. Investors' concerns about inflationary pressures and central banks' interest rate hikes could have contributed to the negative market movement.
• 2. Insider selling: an article from EIN News Pharmaceuticals highlights that MML Investors Services LLC decreased its stock position in MRK. This insider selling activity might have signaled a lack of confidence in the company's future prospects, leading to a bearish sentiment among other investors.
• 3. Cancer treatment competition: an article from Benzinga discusses the pharmaceutical industry's ongoing battle against cancer. The mention of Moderna Inc (MRNA) and Merck (MRK) collaborating on a late-stage study for a skin-cancer combination treatment could have raised concerns about potential competition for MRK's existing cancer therapies. This news might have impacted investor sentiment and contributed to the bearish movement in MRK's stock.
• 4. Long-term follow-up data: an article from Wallstreet:Online mentions the publication of long-term follow-up data for GARDASIL9, a vaccine developed by Merck. While this news is positive, it might not have had an immediate impact on the stock price. Therefore, it is less likely to be a significant factor in the bearish movement observed today.
• Overall, the bearish movement in MRK's stock today could be attributed to the combination of market sentiment, insider selling, and potential competition in the cancer treatment space.

03.01.2026 - MRK Stock was up 2.0%

• Merck & Co. (MRK) stock saw an uptick following the release of robust Q4 2025 financial results and positive FY 2026 earnings outlook.
• Optimism surrounds Merck's acquisitions and broad pipeline diversification, especially looking beyond the exclusivity of Keytruda, driving the positive market sentiment.
• An educational campaign by Bristol Myers Squibb and Johnson & Johnson about the factor XIa pathway may be influencing the upward movement, shining a light on the potential of novel anticoagulants for cardiovascular and thromboembolic conditions.
• Positive remarks by Jim Cramer regarding Merck's future prospects and its expansion beyond Keytruda are likely bolstering investor confidence in the company's growth trajectory.

03.01.2026 - MRK Stock was up 6.2%

• Reported impressive Q4 2025 sales and profit figures, beating analyst estimates, driven by strong demand for KEYTRUDA and benefits from recent acquisitions.
• Despite the positive earnings, the cautious 2026 outlook, lower-than-expected guidance, and concerns over the impact of the Cidara acquisition led to initial pre-market stock decline.
• Analysts and experts remain optimistic about Merck's strategic acquisitions, diversified pipeline, and upcoming catalysts, highlighting the company's long-term potential.
• The market seems to be balancing Merck's current financial performance with future growth prospects and potential challenges in specific product sales, such as GARDASIL in China.

30.06.2024 - MRK Stock was down 5.3%

• Merck reported strong Q2 earnings with revenue and EPS beating expectations, driven by robust sales of Keytruda, a cancer immunotherapy drug.
• Despite the positive earnings report, the market movement for MRK today could be attributed to concerns over acquisition costs impacting the annual profit forecast, leading to a bearish sentiment among investors.
• The overall market sentiment was slightly positive with US futures rising ahead of major earnings reports and the Federal Reserve meeting, indicating a cautious optimism among investors.
• The news about CrowdStrike dropping in premarket trading due to potential damages sought by Delta Air Lines could have added to the negative sentiment in the market, impacting MRK's stock price.

30.06.2024 - MRK Stock was down 9.5%

• Merck & Co's stock experienced a strong bearish movement today after the company lowered its full-year adjusted profit guidance, causing a significant drop in share price.
• Despite beating earnings per share and revenue expectations for Q2 2024, the market reacted negatively to the lowered guidance for the future, leading to the stock decline.
• Recommendation to buy Merck on the post-earnings dip may indicate a potential opportunity for investors looking at the long-term prospects of the company beyond the current market reaction.
• The broader market sentiment, with investors awaiting the Federal Reserve's policy decision, likely added to the volatility in tech stocks like Merck, contributing to the bearish movement.

30.06.2024 - MRK Stock was down 9.1%

• Merck's Gardasil sales were impacted by China's corruption crackdown, leading to a slowdown in shipments and spooking investors.
• The company's lowered adjusted EPS guidance contributed to the negative sentiment among investors, causing the stock to slide.
• Amidst a mixed day for U.S. equities, Merck stood out with a notable 8% drop, contrasting with the surge in financials and energy stocks.
• The overall sentiment in the biotech sector, to which Merck belongs, was not favorable, as evidenced by the 10% decline in Merck's stock price.

30.06.2024 - MRK Stock was down 9.3%

• Merck & Co exceeded analyst estimates in earnings per share and revenue for Q2 2024, demonstrating robust financial performance.
• The company reduced its adjusted earnings guidance for full-year 2024, causing investor worries and a decline in the market.
• While the Healthcare sector gained, the Technology sector had mixed outcomes. Merck's decline amid positive news from Healthcare sector suggests internal factors affecting its stock performance.
• The Technology sector's variability, including companies like Nvidia facing declines, implies market forces or competitive pressures influencing investor sentiment and contributing to Merck's downturn.

30.06.2024 - MRK Stock was down 10.2%

• Merck (MRK) swung to profit in Q2 on higher revenues, beating earnings expectations. This positive financial performance should have been a bullish indicator for the stock.
• Despite the strong earnings report, Merck (MRK) experienced a notable bearish movement in the market. This could be attributed to potential concerns about acquisition costs impacting the annual profit forecast.
• The mixed results in the Technology sector and the slight dip in major tech players like Nvidia (NVDA) could have influenced overall market sentiment, indirectly affecting Merck's stock price.
• The robust performance of companies like AbbVie (ABBV) in the Healthcare sector might have diverted investor attention away from Merck, contributing to the bearish movement in MRK's stock.

08.00.2026 - MRK Stock was up 3.3%

• Merck's stock price surged following an upgrade from Wolfe Research to Outperform from Peer Perform, showcasing optimism and confidence in the company's growth outlook.
• Identification as a top long-term growth stock by Zacks Investment Research heightened investor interest in Merck, propelling the stock upwards.
• A strategic partnership between Veeva Systems and BioMarin Pharmaceutical, though unrelated to Merck, underlines industry collaborations that could have a positive impact on market sentiment.
• United Asset Strategies Inc. raised its stake in Merck, indicating institutional confidence in the company's future performance and strategic endeavors.